Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II First-in-Human TL-895 in B-cell Malignancies and CLL/SLL
2024-516691-14-00Phase 2Completed
- Sponsor
- Telios Pharma
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of TL-895 in B-cell malignancy and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (7 arms), sponsored by Telios Pharma. Started Dec 2024; status: completed.
02
Drugs
TL-895
03
Conditions
B-cell malignancychronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2024-516691-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516691-14-00.